|
Jun 6
|
Valneva reports data from Phase II chikungunya vaccine trial in children
|
|
Jun 5
|
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
|
|
Jun 5
|
[Valneva SE] Declaration of shares and voting rights - May 2025
|
|
May 7
|
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
|
|
Feb 18
|
Valneva hits 2024 sales target but plans lower cash burn in 2025
|
|
Feb 18
|
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
|
|
Feb 17
|
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
|
|
Oct 11
|
High Growth Tech Stocks In France October 2024
|
|
Oct 10
|
Valneva Hosts Investor Day in New York City
|
|
Oct 9
|
Valneva SE (INRLF) (H1 2024) Earnings Call Highlights: Navigating Growth Amidst Revenue Challenges
|
|
Oct 9
|
Exclusive Networks And 2 High Growth Tech Stocks In France
|
|
Oct 8
|
Exploring Three High Growth Tech Stocks in France
|
|
Jul 26
|
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
|
|
Jul 4
|
Declaration of shares and voting rights - Valneva SE - June 30, 2024
|
|
Jul 1
|
Valneva’s chikungunya vaccine gains EC’s market authorisation
|
|
Jul 1
|
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®
|
|
Jun 26
|
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
|
|
Jun 24
|
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
|
|
Jun 24
|
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
|
|
May 21
|
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
|